Wegovy and Ozempic maker Novo Nordisk has agreed to buy Cardior Pharmaceuticals for $1.11 billion. The acquisition is part of Novo Nordisk’s larger strategy to build a portfolio of therapies in cardiovascular disease.
Wegovy and Ozempic maker Novo Nordisk has agreed to buy Cardior Pharmaceuticals for $1.11 billion. The acquisition is part of Novo Nordisk’s larger strategy to build a portfolio of therapies in cardiovascular disease.
Copyright © 2024 | WordPress Theme by MH Themes
